The pharmaceutical Janssen, belonging to the American multinational Johnson & Johnson, plans to have the vaccine against COVID-19, in which phase III trials participate Spain, in the second half of 2021 at a price lower than 10 dollars (about 8.4 euros at the current exchange rate).
This was revealed this Thursday by the vice president of the Executive Committee of Johnson & Johnson, Joaquín Duato, in a conference at the Sectorial Meeting of the Health Sector, organized by IESE Business School, with the collaboration of the consulting firm McKinsey & Company.
The study, approved yesterday in Spain by the Spanish Agency for Medicines and Health Products, plans to guarantee the vaccine “sometime in the first or second half of 2021 “, has declared.
The first clinical results from Pfizer and Moderna, with 95% efficacy, are figures that represent “good omens” for the rest of the pharmaceutical companies focused on the same protein.
As reported by the Johnson & Johnson executive, the pharmaceutical company has worked in the supply chain to be able to offer a billion vaccines in 2021 through a collaborative network.
“During the next six months there will be good news, we will see how these effective vaccines will be available to the public,” emphasized Duato, who took the opportunity to emphasize that the vaccine his team is working on will also will guarantee “the standards of quality and safety“announced by other companies in the sector.
The Duato explained on Twitter JNJ’s efforts to develop a candidate vaccine and “the many valuable lessons we have learned along the way.”
I was honored to join @IESEBschool today for their Healthcare 2020 annual industry event, this year focused on combating #COVID19. I discussed #JNJ‘s efforts to develop a vaccine candidate and the many valuable lessons we’ve learned along the way. pic.twitter.com/gYscqf04tV
– Joaquin Duato (@joaquinduato) November 19, 2020
The speaker applauded the collaboration between partners in the pharmaceutical industry to find a vaccine: “It is not a competitive situation, it is a social issue and a global crisis in which we will need several vaccines, not just one, because we must vaccinate millions of people. “
To guarantee the vaccination of the population, Johnson & Johnson works together with governments on access and distribution plans, such as COVAX, a project to which they will allocate 500 million doses of their production for the lowest-income countries.
From the multinational they assure that the price will not focus on profit: “We will seek to guarantee access to the vaccine in all territories, the price will not be more than 10 dollars per vaccine.”
Spain is one of the participants in the Janssen study, currently in phase III, to be carried out in the University of Navarra Clinic, the La Paz University Hospital, the Quirón Salud Madrid University Hospital, the La Princesa University Hospital, the Quirón Salud Barcelona Hospital, the Vall d’Hebron University Hospital, the Hospital Clínic de Barcelona and the Germans Trias i Pujol Hospital in Badalona.
Digsmak is a news publisher with over 12 years of reporting experiance; and have published in many industry leading publications and news sites.